Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinoma

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1908-1916

  Begum, Asma ^a,b,d   Imoto, Issei ^a,c   Kozaki, Ken ichi ^a,c   Tsuda, Hitoshi ^c,e   Suzuki, Emina ^a   Amagasa, Teruo ^b   Inazawa, Johji ^a,b,c,d  

^a Medical Research Institute and School of Biomedical Science   (Japan)

^b Kyushu Universitay   (Japan)

^c Hard Tissue Genome Research Center   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

P21 ACTIVATED KINASE 4;

ADULT; AGED; AMPLICON; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 12Q; CHROMOSOME 19Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HEAD AND NECK SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 19; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; P21-ACTIVATED KINASES; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 70349591634     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01252.x     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Brinkman BM, Wong DT. Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol 2006, 18:228-33.
3. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006, 7:77-82.
4. Martin CL, Reshmi SC, Ried T, et al. Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature. Oral Oncol 2008, 44:369-82.
5. Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol 1999, 9:319-25.
6. Savelyeva L, Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett 2001, 167:115-23.
7. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998, 20:207-11.
8. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004, 95:559-63.
9. Suzuki E, Imoto I, Pimkhaokham A, et al. PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation. Oncogene 2007, 26:7921-32.
10. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992, 89:9267-71.
11. Kallioniemi A, Kallioniemi OP, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 1994, 91:2156-60.
12. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995, 64:280-5.
13. Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 2009, 28:209-17.
14. General Rules for Clinical Studies on Head and Neck Cancer 2001, 3rd edn, Tokyo, Kanahara
15. Sobin LH, Wittekind C. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours 2002, 19-52. In, 6th edn, New York, Wiley-Liss
16. Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004, 165:71-81.
17. Callow MG, Clairvoyant F, Zhu S, et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 2002, 277:550-8.
18. Huntsman DG, Chin SF, Muleris M, et al. MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene 1999, 18:7975-84.
19. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000, 157:787-94.
20. Tang TC, Sham JS, Xie D, et al. Identification of a candidate oncogene SEI-1 within a minimal amplified region at 19q13.1 in ovarian cancer cell lines. Cancer Res 2002, 62:7157-61.
21. Deng X, Ewton DZ, Li S, et al. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. Cancer Res 2006, 66:4149-58.
22. Moniaux N, Nemos C, Schmied BM, et al. The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene 2006, 25:3247-57.
23. Kuuselo R, Savinainen K, Azorsa DO, et al. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 2007, 67:1943-9.
24. Kikuchi S, Honda K, Tsuda H, et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res 2008, 14:5348-56.
25. Weinstein IB. Cancer: addiction to oncogenes - The Achilles heal of cancer. Science 2002, 297:63-4.
26. Abo A, Qu J, Cammarano MS, et al. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J 1998, 17:6527-40.
27. Eswaran J, Soundararajan M, Kumar R, Knapp S. UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci 2008, 33:394-403.
28. Qu J, Li X, Novitch BG, et al. PAK4 kinase is essential for embryonic viability and for proper neuronal development. Mol Cell Biol 2003, 23:7122-33.
29. Qu J, Cammarano MS, Shi Q, Ha KC, de Lanerolle P, Minden A. Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol 2001, 21:3523-33.
30. Liu Y, Xiao H, Tian Y, et al. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res 2008, 6:1215-24.
31. Cammarano MS, Nekrasova T, Noel B, Minden A. Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Methods Mol Biol 2005, 25:9532-42.
32. Gnesutta N, Qu J, Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem 2001, 276:14414-9.